- Home
- NBRG vs ACET Comparison
NBRG vs ACET Comparison
Compare NBRG & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBRG | ACET |
|---|---|---|
| Founded | 2021 | 1947 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 77.3M |
| IPO Year | 2026 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NBRG | ACET |
|---|---|---|
| Price | $9.96 | $8.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $48.33 |
| AVG Volume (30 Days) | 1.3K | ★ 98.7K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.59 | $0.46 |
| 52 Week High | $9.96 | $9.47 |
Technical Indicators
Market Signals| Indicator | NBRG | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 70.52 | 58.89 |
| Support Level | $9.90 | $7.36 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.01 | 0.58 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 99.78 | 73.84 |
Price Performance
Historical ComparisonAbout NBRG Newbridge Acquisition Limited Class A Ordinary Share
Newbridge Acquisition Ltd is a blank check company.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).